Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis

Martin Roesel1
Christoph Tappeiner2
Arnd Heiligenhaus1,3
Carsten Heinz1,3
1Department of Ophthalmology, St Franziskus-Hospital, Muenster, Germany; 2Department of Ophthalmology, Inselspital, University of Bern, Switzerland; 3University Duisburg-Essen, Germany

Abstract: Voclosporin, a novel immunomodulatory drug inhibiting the calcineurin enzyme, was developed to prevent organ graft rejection and to treat autoimmune diseases. The chemical structure of voclosporin is similar to that of cyclosporine A, with a difference in one amino acid, leading to superior calcineurin inhibition and less variability in plasma concentration. Compared with placebo, voclosporin may significantly reduce inflammation and prevent recurrences of inflammation in patients with noninfectious uveitis. Future studies have to show if these advantages are accompanied by greater clinical efficacy and fewer side effects compared with the classic calcineurin inhibitors.

Keywords: uveitis, immunosuppression, voclosporin

Introduction
Noninfectious uveitis is often chronic and relapsing, and typically affects people aged 20–60 years, ie, the working population. Nevertheless, children and older people can also be affected, albeit less frequently, and may have different underlying diseases.1–3 Visual impairment occurs in many patients with uveitis, but blindness is a relatively rare complication in recent decades due to more potent drugs and more aggressive treatment strategies. Worldwide, uveitis is one of the five most important reasons for visual loss and accounts for 10% of cases of blindness due to secondary complications, eg, macular edema.1,4,5

Patients with uveitis reported markedly reduced general and vision-related quality of life compared with normal subjects.6 The vision-related quality of life in patients with noninfectious uveitis is even worse compared with patients with infectious uveitis, and this is attributed to the often chronic relapsing course of the noninfectious disease.7 Furthermore, general quality of life in patients with uveitis on chronic systemic immunosuppressive treatment has been shown to be reduced, being related to visual acuity and disease duration.8 Therefore, treatment of uveitis with immunomodulatory agents has to be not only effective but also well tolerated by patients in terms of safety and quality of life.

Noninfectious uveitis may be limited to the eye itself (idiopathic uveitis) or be associated with a systemic autoimmune disease. The pathogenesis of noninfectious uveitis is thought to be due to a disruption of ocular immunotolerance. The blood retinal barrier and blood aqueous barrier are anatomical barriers that protect the eye from otherwise harmful immune reactions. Furthermore, the aqueous fluid and vitreous contain immunosuppressive cytokines (eg, transforming growth factor beta, vasoactive
intestinal polypeptide, alpha-melanocyte-stimulating hormone, and calcitonin-releasing protein) regulating the activity of leukocytes. If ocular immune privilege is broken, the uvea and adjacent tissue are infiltrated and damaged by inflammatory cells. Bacterial and viral antigens may trigger immune reactions, as well as the body’s own antigens, mediated by trauma or inflammation. Uveitis is an autoimmune disease primarily mediated by CD4-positive T helper cells. These T cells produce a number of proinflammatory cytokines, such as interferon gamma and several types of interleukins. These cytokines spread inflammation to further immune cells.

Corticosteroids are usually the first-line treatment in autoimmune uveitis. Application (topical, periocular, intravitreal injection, oral formulations) and dosing depend on the anatomical type of uveitis according to the Standardization of Uveitis Nomenclature classification and severity of inflammation. If inflammation is restricted to the anterior eye chamber, corticosteroid eyedrops are initiated. Systemic corticosteroids are administered for inflammation of the posterior eye segment including the vitreous. If inflammation is severe, the initial dosage is usually 1 mg/kg body weight, decreasing by 10 mg weekly. Low-dose corticosteroids at a dosage around 0.1 mg/kg body weight are often given as maintenance therapy to prevent further flares. Second-line immunosuppressive therapy is administered if inflammation requires high corticosteroid dosages over the long term or if low-dose treatment is accompanied by adverse effects. Antimetabolites (azathioprine, methotrexate) and T cell inhibitors (cyclosporine, mycophenolic acid) are the most commonly used corticosteroid-sparing drugs in nonfertile uveitis. Azathioprine is a prodrug that is metabolized into 6-mercaptopurine, which acts as a purine synthesis inhibitor, inhibiting DNA synthesis and consequently proliferation of cells. Azathioprine is usually administered at a dosage of 2 mg/kg daily. Azathioprine is moderately effective as a single corticosteroid-sparing immunosuppressive agent in terms of controlling inflammation and having corticosteroid-sparing benefits, but requires several months to achieve treatment goals. Methotrexate inhibits tetrahydrofolate synthesis by inhibiting the enzyme dihydrofolate reductase. Folic acid is important for the synthesis of DNA, RNA, and proteins. Methotrexate reduces B and T cell proliferation, and is commonly used at a dosage of 15–25 mg weekly in adult patients with uveitis. Methotrexate is also effective for intraocular lymphoma when given directly into the eye. Cyclosporine A binds to cyclophilin, thereby inhibiting calcineurin. Calcineurin dephosphorylates the nuclear factor of activated T cells, which is responsible for the transcription of interleukin-2. Cyclosporine A thus leads to reduced functioning of T cells. Cyclosporine A at a dosage of 151–250 mg/day is modestly effective for controlling intraocular inflammation. Mycophenolic acid inhibits inosine monophosphate dehydrogenase, which is important for purine synthesis. Mycophenolic acid reduces proliferation of B and T lymphocytes. At the preferred dosage of 720 mg twice daily, mycophenolic acid is effective and well tolerated. A similar drug, mycophenolate mofetil, has proven to be effective in managing ocular inflammation in approximately half of patients treated.

Nowadays, biologic agents, such as tumor necrosis factor alpha inhibitors (adalimumab, infliximab) have demonstrated good efficacy in otherwise treatment-refractory uveitis. However, high treatment costs and the lack of randomized controlled trials limit their use to selected cases.

### Chemical and pharmacologic data

Voclosporin (Lux Biosciences Inc, Jersey City, NJ) was developed by Isotechnika Pharma Inc, Edmonton, AB, Canada, for the treatment of autoimmune diseases and prevention of allograft rejection. The molecular structure is very similar to that of cyclosporine A, with the exception of a functional group in an amino acid. The molecular structure is already shown elsewhere. Voclosporin is a calcineurin inhibitor leading to inhibition of activation of T cells and a decrease of proinflammatory cytokine (interleukin-2, interleukin-4, interferon gamma) production. Voclosporin consists of two isomers, ie, a trans and a cis isomer. These two isomers differ in the orientation of one modified functional group. While early clinical and nonclinical studies were performed using a virtually equal mixture of both isomers, ie, ISA247, nowadays the clinical studies use the more potent trans isomer, ie, LX211. The blood concentrations of voclosporin may be quantified by mass spectrometry. ISA247/LX-211 demonstrated good absorption after oral administration in rabbits, cats, and dogs. The half-life is 6.0–8.8 hours and systemic exposure is dose-related. Time to peak concentration is 1.5–2.0 hours after oral administration. ISA247/LX-211 undergoes extensive first-pass metabolism, involving the cytochrome P450 enzyme. Fecal excretion is the primary route of elimination.

ISA247 leads to comparable or even higher inhibition of lymphocyte proliferation, T cell activation, and cytokine production than that achieved by cyclosporine A in nonhuman primates. Allografts in monkeys treated with ISA247 survive longer than those treated with cyclosporine A. This superior immunosuppressive potency of ISA247 compared
Table 1 Safety data from clinical trials of voclosporin for plaque psoriasis

| Study          | Most frequently reported adverse events:                                                                 |
|---------------|----------------------------------------------------------------------------------------------------------|
| Bissonnette et al33 | nausea, headache, abnormal chemistry changes 0.5 mg/kg/day group showed a similar percentage of side effects compared with placebo, and no change in mean serum creatinine levels 1.5 mg/kg/day group showed a significant increase in mean creatinine levels Neither group had a significant increase in infection rate, mean blood pressure, serum lipid parameters, or significant electrocardiogram parameter alterations |
| Papp et al34 | Most frequently reported adverse events: headache, nasopharyngitis, and upper respiratory tract infections All three groups (0.4, 0.6, 0.8 mg/kg/day) showed no significant changes in renal function, blood pressure, or mean lipid concentrations at 12 or 24 weeks |

With cyclosporine A is also observed in vitro.30 Voclosporin (LX211) has achieved effective suppression of experimental uveitis in rats, and furthermore inhibition of human T cell proliferation and function in vitro.31

Clinical data

In a 12-week, randomized, double-blind, placebo-controlled Phase II study of 201 patients with plaque psoriasis, ISA247 appeared safe and effective for treating moderate to severe psoriasis. The most effective concentration was 1.5 mg/kg/day, but serum creatinine increased in this patient group.33 The efficacy of ISA247 in psoriasis was confirmed by a Phase III study of 451 patients for 24 weeks. The highest administered dose (0.4 mg/kg twice a day) achieved the best results for psoriasis area and severity index.34 Both psoriasis studies examined quality of life between placebo and verum groups and found the highest serum concentrations to improve disease-related quality of life.35,36 Further studies are evaluating the effect of voclosporin in kidney and renal transplantation and the safety and tolerability of the ophthalmic solution in patients with keratoconjunctivitis sicca.

Published data on side effects in patients treated with voclosporin for uveitis are limited (see Table 1). The mode of action of voclosporin is similar to that of cyclosporine A, with probably similar side effects. Data on development of malignancy while on treatment with cyclosporine A for inflammatory ocular disease are also scarce. Lane et al did not observe an increased risk of malignancy in patients with severe ocular inflammatory eye disease treated with systemic immunosuppressive agents compared with patients treated with systemic corticosteroids.37 Kempen et al followed on with data showing that calcineurin inhibitors would probably not increase cancer risk to a degree that outweighs the expected benefits of therapy for ocular inflammation.38 Voclosporin demonstrated less nephrotoxicity compared with calcineurin in animal studies.32

Uveitis trials

Up until now, three clinical studies of voclosporin in the treatment of noninfectious uveitis have been performed. The LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) clinical development program was initiated in 2007 by Lux Biosciences Inc to assess the safety and efficacy of voclosporin for the treatment, maintenance, and control of all forms of noninfectious uveitis. The aim of the LUMINATE program, which was recently presented by Anglade et al, was to ensure that voclosporin would become the first corticosteroid-sparing agent to be approved by the US Food and Drug Administration for noninfectious uveitis. Three randomized, double-blind, placebo-controlled, Phase II/III trials in patients with noninfectious, sight-threatening uveitis were performed. The first study included patients with active intermediate, anterior and intermediate, posterior, or panuveitis. The second study included patients with quiescent intermediate, anterior and intermediate, posterior, or panuveitis in patients requiring systemic immunosuppression. The third study included patients with active anterior uveitis requiring systemic immunosuppression. The final results of the three studies are not yet comprehensively published, but some data are available.23,39,40 In patients with active intermediate, posterior, and panuveitis, voclosporin 0.4 mg/kg and 0.6 mg/kg twice daily reduced inflammation by about 50% compared with 29% in the placebo group at 16 and 24 weeks. Uveitis recurrences were reduced by 50% in the group with quiescent uveitis. In all three studies, 96%–98% of patients were able to reduce their oral prednisolone dosage to ≤5 mg daily. However, no significant effect for voclosporin was observed for anterior uveitis.

Nearly 20% of patients treated with 0.6 mg twice daily experienced deterioration of renal function. This was seen in only 8.2% of patients in the 0.4 mg/kg group. Hypertension was experienced by 7.5% of patients in the 0.4 mg/kg group and by 10.3% of patients in the 0.6 mg/kg group.41

The recently presented data are very promising, but the Food and Drug Administration has requested an additional clinical trial prior to final approval of voclosporin for the
treatment of noninfectious uveitis. Therefore, Lux Biosciences Inc is currently planning a Phase III study to assess the efficacy and safety of voclosporin in patients with active noninfectious intermediate, posterior, or panuveitis. The mean change in vitreous haze from baseline to 12-week follow-up and time to treatment failure is the primary outcome measure of this trial. Secondary outcome measures are mean daily systemic corticosteroid dose during weeks 12–24, time to augmentation with corticosteroid therapy, and mean change from baseline in the Vision Specific Role Difficulties subscale of the National Eye Institute Visional Functioning Questionnaire. If successful, voclosporin may become the first corticosteroid-sparing agent approved by the Food and Drug Administration for the treatment of noninfectious uveitis.

**Conclusion**

Voclosporin, a novel immunomodulatory drug inhibiting the calcineurin enzyme, may significantly reduce inflammation and prevent recurrences of inflammation in patients with noninfectious uveitis. If the additional Phase III study confirms its effectiveness, voclosporin may become the first immunosuppressive drug approved by the Food and Drug Administration for the treatment of noninfectious uveitis.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: A literature survey. *Br J Ophthalmol.* 1996;80:844–848.
2. Zierhut M, Michels H, Stubiger N, Besch D, Deuter C, Heiligenaus H. Uveitis in children. *Int Ophthalmol Clin.* 2005;45:135–156.
3. Zierhut M, Baatz H, Coupland S, Deuter C, Heiligenaus H, Heinz C. Uveitis and the aging. *Ophthalmologe.* 2006;103:765–772. German.
4. Nussenblatt RB. The natural history of uveitis. *Int Ophthalmol.* 1990;14:303–308.
5. Rothova A, Suttorp-van Schulten MS, Frits TW, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. *Br J Ophthalmol.* 1996;80:332–336.
6. Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. *Arch Ophthalmol.* 2001;119:841–849.
7. Mello PR, Roma AC, Moraes HV Jr. Analysis of the life quality of infectious and non-infectious patients with uveitis using the NEI-VFQ-25 questionnaire. *Arq Bras Oftalmol.* 2008;71:847–854. Portuguese.
8. Misericocchi E, Modorati G, Mosconi P, Colucci A, Bandello F. Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment. *Ocul Immunol Inflamm.* 2010;18:297–304.
9. Streilein JW. Ocular immune privilege: Therapeutic opportunities from an experiment of nature. *Nat Rev Immunol.* 2003;3:879–889.
10. Taylor A. A review of the influence of aqueous humor on immunity. *Ocul Immunol Inflamm.* 2003;11:231–241.

11. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. *Surv Ophthalmol.* 2001;46:209–233.
12. Forrester JV. Uveitis: Pathogenesis. *Lancet.* 1991;338:1498–1501.
13. Nussenblatt RB. Proctor lecture. Experimental autoimmune uveitis: Mechanisms of disease and clinical therapeutic indications. *Invest Ophthalmol Vis Sci.* 1991;32:3131–3141.
14. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol.* 2005;140:509–516.
15. Pasadnikha S, Kempen JH, Newcomb CW, et al. Azathiprione for ocular inflammatory diseases. *Am J Ophthalmol.* 2009;148:500–509.
16. Ali A, Rosenbaum JT. Use of methotrexate in patients with uveitis. *Clin Exp Rheumatol.* 2010;28:S145–S150.
17. Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. *Ophthalmology.* 2011;117:576–584.
18. Deuter CM, Doycheva D, Stubiger N, Zierhut M. Mycophenolate sodium for immunosuppressive treatment in uveitis. *Ocul Immunol Inflamm.* 2009;17:415–419.
19. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate molftel for ocular inflammation. *Am J Ophthalmol.* 2010;149:423–432.
20. Pleyer U, Mackensen F, Winterhalter S, Stubiger N. Anti-TNF-alpha treatment for uveitis. Analysis of the current situation. *Ophthalmologe.* 2011;108:13–20. German.
21. Dumont FJ. ISAtx-247 (Isotechnika/Roche). *Curr Opin Investig Drugs.* 2004;5:542–550.
22. Anglade E, Aspeslet LJ, Weiss SL. A new agent for the treatment of noninfectious uveitis: Rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. *Clin Ophthalmol.* 2008;2:693–702.
23. Deuter CM. Systemic voclosporin for uveitis treatment. *Ophthalmologe.* 2010;107:672–675. German.
24. Anglade E, Yatscoff R, Foster R, Grau U. Next-generation calcineurin inhibitors for ophthalmic indications. *Expert Opin Investig Drugs.* 2007;16:1525–1540.
25. Kuglstatter A, Mueller F, Kusznir E, et al. Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). *Acta Crystallogr D Biol Crystallogr.* 2011;67:119–123.
26. [No authors listed]. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R–1524. Drugs R D. 2007;8:103–112.
27. Handy R, Trepanier D, Scott G, Foster R, Freitag D. Development and validation of a LC/MS/MS method for quantifying the next generation calcineurin inhibitor, voclosporin, in human whole blood. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2008;874:57–63.
28. Gregory CR, Kyles AE, Bernestein L, et al. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. *Transplantation.* 2004;78:681–685.
29. Stalder M, Birsan T, Huckle RW, Panagia RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. *J Heart Lung Transplant.* 2003;22:1343–1352.
30. Birsan T, Dambri D, Freitag DG, Yatscoff RW, Morris RE. The novel calcineurin inhibitor ISA247: A more potent immunosuppressant than cyclosporine in vitro. *Transpl Int.* 2005;17:767–771.
31. Cunningham MA, Austin BA, Li Z, et al. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. *Invest Ophthalmol Vis Sci.* 2009;50:249–255.
32. Aspeslet L, Freitag T, Trepanier D, et al. ISA(TX)247: A novel calcineurin inhibitor. *Transplant Proc.* 2001;33:1048–1051.
33. Bissonnette R, Papp K, Poulin Y, et al. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. *J Am Acad Dermatol.* 2006;54:472–478.
34. Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: A randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1337–1342.
35. Gupta AK, Langley RG, Lynde C, et al. ISA247: Quality of life results from a phase II, randomized, placebo-controlled study. J Cutan Med Surg. 2008;12:268–275.
36. Kunynetz R, Carey W, Thomas R, Toth D, Trafford T, Vender R. Quality of life in plaque psoriasis patients treated with voclosporin: A Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study. Eur J Dermatol. 2011;21:89–94.
37. Lane L, Tamesis R, Rodriguez A, et al. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology. 1995;102:1530–1535.
38. Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: critical assessment of the evidence. Am J Ophthalmol. 2008;146:802–812.
39. Bodaghi B, Barisani-Asenbauer T, Foster CS; The Luminate Study Group. Luveniq (LX211/voclosporin) as corticosteroid-sparing therapy in clinically quiescent sight-threatening noninfectious uveitis: Results of the LX211-202 study of the LUMINATE clinical program. Presentation at the annual meeting of the American Academy of Ophthalmology, October 24–27, 2009, San Francisco, CA.
40. Nguyen QD, Bodaghi B, Rosenbaum JT, et al; The Luminate Study Group. Voclosporin (LX211) as corticosteroid-sparing therapy for posterior active sight-threatening noninfectious uveitis: Results of the LX211-201 study of the LUMINATE program. Presentation at the annual meeting of the American Academy of Ophthalmology, October 24–27, 2009, San Francisco, CA.
41. Boughton B. Oral voclosporin shows promise for noninfectious uveitis. Medscape Today news. 2009 Available from: http://www.medscape.com/viewarticle/712032. Accessed November 9, 2009.